In Recent News

VisionGate® Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
Press Release, October 19, 2017

VisionGate Hires Prominent Pathologist as Medical Director, VisionGate, Inc.
Press Release, June 7, 2017

Ahwatukee bio-tech company focusing on cure for lung cancerAhwatukee Foothills News, November 2016

Arizona-based Trinnovate Ventures invests in 4 start-upsArizona Business Magazine, October 2016

Tiny Channels, Giant DreamsCancer Cytopathology, July 2016

VisionGate’s LuCED Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of PulmonologistsAZBio, June 2016

Trinnovate Invests Heavily in VisionGate’s Lung Cancer Clinical TrialsLung Disease News, March 2016

Meet the Finalists for Healthcare Leadership Awards Arizona Business Magazine, March 2016

VisionGate Receives Strategic Investment from Trinnovate VenturesBioPortfolio, March 2016

Biotech Showcase 2016 Interview: Diagnostics company VisionGate migrates into therapeutics –  EBD Group, February 2016

Rights to Patent for Lung Cancer Prevention Drug Iloprost Acquired by VisionGateLung Disease News, January 2016

Phoenix biotech firm expands portfolio with new treatment to prevent lung cancerPhoenix Business Journal, January 2016

Phoenix firefighters get free lung-cancer testingPhoenix Business Journal, December 2015

Grant funds cancer test for Phoenix firefightersArizona Republic, December 2015

Phoenix company develops technology to save lives KTVK Channel 3 and KPHO Channel 5, October 2015

How this Phoenix company is one step closer to saving livesPhoenix Business Journal, October 2015

Making LIFE Better:  VisionGate Receives AZBio Fast Lane HonorsYahoo! Finance, September 2015

How 3 Arizona biotech companies set the pace Arizona Business Magazine, September 2015

Significant Lung Cancer Screening Study Published in the American Cancer Society Journal, Cancer CytopathologyBioSpace, July 2015

AZ Commerce Authority names 25 semifinalists in latest Innovation Challenge – Phoenix Business Journal, May 2015

25 startup finalists in Spring 2015 ACA Innovation Challenge – AZ Tech Beat, May 2015

AZBio members VisionGate and NextPotential in Innovation Challenge Top 25 –, May 2015

VisionGate Named “Bioscience Company of the Year” at Healthcare Leadership Awards Arizona Business Magazine, April 2015

World Renowned Surgeon Joins VisionGate Medical Advisory BoardPulmonary Cell News, April 2015

Anatomy of a med-tech startup:  VisionGateArizona Republic, March 2015

Medical metamorphosis: Doctors as entrepreneurs Arizona Republic, March 2015

Dignity Health Arizona Invest in VisionGate – Arizona Business Magazine, February 2015

VisionGate earns two Best in Biz Awards for innovationArizona Business Magazine, December 2014

VisionGate CEO Alan Nelson, PhD, and President Scarlett Spring Among Arizona’s Top Business LeadersArizona Business Magazine, December 2014

President Scarlett Spring speaks at University of Arizona College of Medicine’s Star Trek event – CBS 5, October 2014

Executive Inc:  Scarlett Spring cheers on biotech community by leadingPhoenix Business Journal, September 2014

People in Places:  VisionGate – Medical Device Daily, June 2014

VisionGate Adds 3 Prominent DirectorsAZ Business Magazine, June 2014

VisionGate Adds Three Prominent Board Directors –, June 2014

Lung cancer test shows high sensitivity, specificity, and early stage detectionMedical Device Daily, May 2014

New Study Shows High Sensitivity and Specificity for VisionGate’s LuCED Test to Help Detect Lung Cancer EarlierReuters, May 2014

Positioned for Growth:  Women Entrepreneurs (featuring President Scarlett Spring) – ASU’s Walter Cronkite School of Journalism, April 2014

USC Alumnus Attacks Lung CancerUSC Dornsife, February 2014

The computer will see you nowNature Magazine, October 2013

Detecting Lung Cancer with Just a CoughHealthline News, October 2013


Latest Press Releases

VisionGate Hires Renowned Chief Medical Officer Dr. Javier Zulueta

VisionGate’s LuCED® Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of Pulmonologists

VisonGate Receives Strategic Investment from Trinnovate Ventures

VisionGate to Present at Leerink Partners Global Healthcare Conference

Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost

VisionGate’s First Product, LuCED®, Shows Promise for Screening of Lung Cancer:  Company Presents Blinded Trial Data at WCLC 2015

Two articles published in Cancer Cytopathology demonstrate potential for lung cancer screening using sputum

World renowned surgeon Dr. Harvey Pass joins VisionGate’s Medical Advisory Board

Dignity Health in Arizona Invests in VisionGate

New Data Demonstrates VisionGate’s LuCED® Test Able to Detect Early Lung Cancer — Even from Small Nodules

VisionGate Adds Three Prominent Board Directors

New Study Shows High Sensitivity and Specificity for VisionGate’s LuCED® Test to Help Detect Early Lung Cancer

VisionGate to Present Early Lung Cancer Detection Data at ASCO

VisionGate presents clinical data at IASLC meeting showing its Cell-CT 3D imaging platform detects lung cancer with high sensitivity and specificity

VisionGate reports advances in its Cell-CT™ automated 3-D cell analysis platform at ASC 2012 Scientific Meeting

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.

Copyright 2018 - VisionGate, Inc.